Medical Access and Reimbursement in Turkey

Currently classified as a strictly controlled substance under Turkey’s national drug control framework, with no authorised medical use outside of approved clinical research. This is reflected in Turkish summaries of national drug scheduling which reference the Law on the Control of Narcotic Drugs and list classical psychedelics as illegal for possession, cultivation or distribution except within regulated research contexts #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA (ecstasy) is criminalised for possession, manufacture and distribution in Turkey, and there is no routine medical/ reimbursed pathway for MDMA-assisted therapy in the national health system. Public reporting and national legal summaries describe MDMA as prohibited outside research. #.

Esketamine (nasal spray, marketed internationally as SPRAVATO) is documented in Turkish-language product information materials and leaflet translations that reference local regulatory tracking (TİTCK) identifiers and safety guidance for administration, indicating the product has been registered/introduced to Turkish pharmacy information channels; such product information emphasises specialist administration and cardiovascular monitoring. However, there is no public evidence that esketamine is covered as a reimbursed outpatient treatment by Turkey’s Social Security Institution (SGK) as a routine, nationally funded mental‑health therapy, and its use would be expected to follow specialist psychiatry pathways and local hospital procurement rules rather than broad public reimbursement. Clinical/administration guidance in Turkish product texts underscores supervised delivery and monitoring requirements. #; general absence of SGK reimbursement listings for SPRAVATO was confirmed by lack of SGK listing evidence in publicly indexed reimbursement searches (no SGK formulary citation identified).

Ketamine is an established and widely used anaesthetic and analgesic agent in Turkey’s hospitals and emergency departments; Turkish anaesthesia and emergency-medicine literature documents routine ketamine use for procedural sedation, emergency airway management and perioperative anaesthesia, and it is available through standard hospital procurement and used by anaesthesiologists across public and private sectors. Representative Turkish clinical publications describe ketamine use in EDs, paediatric sedation and in combination anaesthesia protocols, demonstrating its entrenched role in medical practice. Off‑label low‑dose (sub‑anaesthetic) ketamine for treatment‑resistant depression is practiced in some private and tertiary psychiatric/anaesthesia centres internationally and in Turkey it may be offered on an off‑label basis within specialist clinics, but such psychiatric applications are not part of a nationally reimbursed, standard SGK mental‑health benefit and would generally be funded out‑of‑pocket or by private insurance on a case-by-case basis. Examples of Turkish clinical literature documenting routine anaesthetic/ procedural ketamine use: Turkish Journal of Emergency Medicine case series and national endoscopy/anesthesia surveys. #; #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT and preparations containing significant amounts of DMT (including many ayahuasca preparations) are controlled substances or treated as illegal if they contain quantifiable DMT; Turkish and international legal summaries indicate DMT is treated as a prohibited psychotropic in Turkey absent special authorisation for research. #; note: international listings emphasise DMT’s scheduling under the 1971 UN Psychotropic Convention and national implementing laws.

5‑MeO‑DMT has been identified in legal compendia as specifically controlled in Turkey (control listing updates note 5‑MeO‑DMT’s inclusion in Turkish controlled‑substances regulations since December 2013), and therefore it carries no authorised medical use outside approved clinical research. Possession, distribution or preparation is prosecutable under narcotics laws. #.

Currently classified in practice as not authorised for routine medical use in Turkey; there is no recognised, reimbursed ibogaine treatment pathway and most national summaries treat ibogaine as not approved and effectively prohibited outside tightly controlled research or unregulated ‘clinic’ settings. Where ibogaine is not explicitly listed in a national schedule it is commonly treated as an unauthorised psychoactive agent subject to narcotics legislation; no SGK‑reimbursed ibogaine programs are documented. International overviews and country‑by‑country legal trackers describe ibogaine as lacking approval and often existing in legal grey zones — the same practical situation applies to Turkey. #.

Preparations containing appreciable quantities of DMT (ayahuasca decoctions) are effectively illegal to import, possess or administer in Turkey outside authorised research; national practice follows international controls for DMT-containing preparations and there is no authorised, reimbursed clinical ayahuasca program. Summary legal resources and country lists treat ayahuasca as prohibited in Turkey absent explicit research or rare administrative exemptions. #; UN and international compendia note DMT scheduling that underpins national controls.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline‑containing cacti (e.g., peyote) or isolated mescaline are illegal to possess or distribute for non‑research purposes in Turkey; no reimbursed medical pathway exists. Country legal summaries and drug‑control law overviews treat mescaline as a prohibited psychotropic. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Synthetic phenethylamines in the 2C family (2C‑B, 2C‑I, etc.) are controlled and prosecuted under Turkish narcotics statutes; there is no medical‑use or reimbursement pathway. #.